胰高糖素样肽-1及其类似物在心血管系统作用的研究进展
摘要
糖尿病是一种严重威胁人类健康的常见病和慢性病.近年来,2型糖尿病患者发生心血管事件的死亡率不断增加.有研究表明,用传统治疗方案强化降糖治疗并不能有效降低2型糖尿病患者心血管事件的死亡率[1-2].在有效控制血糖的同时降低糖尿病相关并发症尤其是心血管事件的风险,对糖尿病患者具有重大意义.胰高糖素样肽-1（GLP-1）是由肠道产生的一种神经内分泌激素,其通过刺激胰岛素分泌、抑制胰高血糖素的分泌、延缓胃排空、抑制食欲减少食物的摄取等方式发挥其糖稳态的作用[3].
出处
《临床内科杂志》
CAS
2013年第7期501-503,共3页
Journal of Clinical Internal Medicine
参考文献22
-
1Patel A,MacMahon S,Chalmers J,et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med,2008,358:2560-2572.
-
2Duckworth W,Abraira C,Moritz T,et al.Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes.N Engl J Med,2009,360:129-139.
-
3Mudaliar S,Henry RR.Incretin Therapies:Effects Beyond Glycemic Control.Am J of Med,2009,122:25-36.
-
4Plamboeck A,Holst J J,Carr RD,et al.Neutral endopeptidase 24.11 and dipeptidyl peptidase Ⅳ are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.Diabetologia,2005,48:1882-1890.
-
5Gardiner SM,March JE,Kemp PA,et al.Possible involvement of GLP-1 (9-36) in the regional haemodynamic effects of GLP-1 (7-36) in conscious rats.Br J Pharmacol,2010,161:92-102.1.
-
6Tomas E,Habener JF.Insulin-like actions of glucagon-like peptide-1:a dual receptor hypothesis.Trends Endocrinol Metab,2010,21:59-67.
-
7Nikolaidis LA,Mankad S,Sokos GG,et al.Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.Circulation,2004,109:962-965.
-
8Read PA,Hoole SP,White PA,et al.A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.Circ Cardiovasc Interv,2011,4:266-272.
-
9L(o)nborg J,Vejlstrup N,Kelbaek H,et al.Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.Eur Heart J,2012,33:1491-1499.
-
10Sokos GG,Nikolaidis LA,Mankad S,et al.Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.J Card Fail,2006,12:694-699.
-
1莫然.瑞典研制出治疗糖尿病的新药[J].糖尿病之友,2004(10):16-16.
-
2赵伟平.不同剂量利拉鲁肽治疗2型糖尿病伴冠心病疗效对比观察[J].医药论坛杂志,2016,37(10):148-149. 被引量：2
-
3江思瑜,梁婵,吴晓光.利拉鲁肽对糖尿病肾病患者炎症因子影响的研究进展[J].中国药房,2017,28(2):280-283. 被引量：31
-
4苏丽红.长效胰高糖素样肽-1治疗肥胖2型糖尿病的临床疗效观察[J].中国医药指南,2014,12(21):216-217. 被引量：1
-
5兰丽珍,辛静.人过氧化物酶体增殖物激活受体γ-胰高糖素样肽-1类似肽融合蛋白的表达和纯化[J].中国药物与临床,2013,13(7):870-872.
-
6王建华.糖尿病新药撷萃[J].药物与人,2013(11):22-23.
-
7赵向英,张晓华.胰高糖素样肽-1与2型糖尿病及中药干预的研究进展[J].大众健康（理论版）,2012(11):243-243.
-
8岳峰,许娟,魏岱林,张铁.不同糖耐量患者肠促胰素水平变化的研究[J].中华临床医师杂志（电子版）,2012,6(17):5323-5325.
-
9张伟,马维青,吕芳,胡国平,孙春萍,张强.初诊2型糖尿病伴腹型肥胖患者胰高糖素样肽-1水平分析[J].中华实用诊断与治疗杂志,2017,31(2):162-164. 被引量：3
-
10丁丽,张绍维,赵文洲,罗晶,王巍,张锦.GLP-1对人脐静脉内皮细胞释放NO的影响及机制的研究[J].现代生物医学进展,2015,15(4):632-634. 被引量：5
